文献速递肝病消化道出血

静脉曲张出血的精准医学:我们实现了吗?

Precision medicine in variceal bleeding: Are we there yet?
PubMed 文献 · J Hepatol · 2020-01-22

本文综述支持基于个体风险特征指导肝硬化静脉曲张出血管理的证据。识别并治疗临床显著性门脉高压可改善无失代偿生存;急性出血时预测失败/再出血风险可早期升级治疗(如先发制人TIPS)改善生存;依据肝功能和血流动力学反应分层可个体化预防再出血。

要点

  • 临床显著性门脉高压是曲张静脉及失代偿的主要决定因素,应筛查监测。
  • 一级预防中识别并治疗临床显著性门脉高压可改善无失代偿生存。
  • 急性曲张出血可预测失败/再出血风险,合适者早期TIPS可改善生存。

核心结论

  • 基于个体风险特征制定治疗可影响预后并提高各临床场景生存。

研究设计与样本

  • 综述评估支持使用个体风险特征进行临床决策及其对结局和生存影响的证据。

主要发现

  • 一级预防中识别并治疗临床显著性门脉高压可改善无失代偿生存。
  • 急性曲张出血时失败和再出血风险可预测,允许早期升级治疗如先发制人TIPS。
  • 基于肝功能和非选择性β受体阻滞剂血流动力学反应分层再出血风险可个体化治疗。

临床怎么用

  • 筛查监测临床显著性门脉高压并据此治疗以改善无失代偿生存。
  • 急性曲张出血预测失败/再出血风险,合适者早期行先发制人TIPS。
  • 依据肝功能和非选择性β受体阻滞剂血流动力学反应分层制定再出血预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Variceal bleeding is one of the most feared complications of portal hypertension in patients with cirrhosis because of its deleterious impact on prognosis. Adequate management of patients at risk of developing variceal bleeding includes the prevention of the first episode of variceal bleeding and rebleeding, and is crucial in modifying prognosis. The presence of clinically significant portal hypertension is the main factor determining the risk of development of varices and other liver-related decompensations; therefore, it should be carefully screened for and monitored. Treating patients with clinically significant portal hypertension based on their individual risk of portal hypertension-related bleeding undoubtedly improves prognosis. The evaluation of liver haemodynamics and liver function can stratify patients according to their risk of bleeding and are no question useful tools to guide therapy in an individualised manner. That said, recent data support the idea that tailoring therapy to patient characteristics may effectively impact on prognosis and increase survival in all clinical scenarios. This review will focus on evaluating the available evidence supporting the use of individual risk characteristics for clinical decision-making and their impact on clinical outcome and survival. In primary prophylaxis, identification and treatment of patients with clinically significant portal hypertension improves decompensation-free survival. In the setting of acute variceal bleeding, the risk of failure and rebleeding can be easily predicted, allowing for early escalation of treatment (i.e. pre-emptive transjugular intrahepatic portosystemic shunt) which can improve survival in appropriate candidates. Stratifying the risk of recurrent variceal bleeding based on liver function and haemodynamic response to non-selective beta-blockers allows for tailored treatment, thereby increasing survival and avoiding adverse events.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Magaz M, Baiges A, Hernández-Gea V, et al. Precision medicine in variceal bleeding: Are we there yet? J Hepatol. 2020. PMID: 31981725. doi:10.1016/j.jhep.2020.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。